What is Calpact?
Calpact operates at the intersection of advanced physics and clinical diagnostics, specializing in the commercialization of photoacoustic computed tomography. Unlike traditional imaging modalities that rely on ionizing radiation, Calpact utilizes light-based PACT technology to deliver high-resolution, functional imaging. Their current product portfolio includes the Single-Breath-Hold PACT system, designed specifically for human breast imaging, and the Single-Impulse Panoramic PACT, which serves the specialized needs of small-animal research. By eliminating the risks associated with radiation, the company is carving out a significant niche in both human and veterinary medicine, offering a safer, more efficient alternative for diagnostic imaging providers and academic research institutions.
How much funding has Calpact raised?
Calpact has raised a total of $43K across 1 funding round:
Debt
$43K
Debt (2021): $43K with participation from PPP
Key Investors in Calpact
PPP
Public-Private Partnership
What's next for Calpact?
With this recent financing, Calpact is expected to prioritize the scaling of its manufacturing capabilities and the expansion of its clinical validation studies. The company's strategic roadmap likely involves deepening its market penetration in the breast imaging sector while simultaneously exploring new applications for its non-ionizing technology. As the firm moves through its current growth phase, the focus will remain on regulatory milestones and the establishment of strategic partnerships with major healthcare providers. By leveraging its unique technological advantage, Calpact is poised to disrupt the status quo in diagnostic imaging, potentially setting a new standard for safety and functional clarity in clinical environments.
See full Calpact company page
